Results 111 to 120 of about 1,361 (136)

Uterine Serous Carcinoma Responds to the WEE1 Inhibitor Adavosertib

Cancer Discovery, 2021
Abstract The overall response rate to adavosertib was 29.4%; no biomarkers predicting response were found.
openaire   +2 more sources

EFFORT: EFFicacy Of adavosertib in parp ResisTance: A randomized two-arm non-comparative phase II study of adavosertib with or without olaparib in women with PARP-resistant ovarian cancer.

Journal of Clinical Oncology, 2021
5505 Background: Wee1 phosphorylates and inhibits cyclin-dependent kinases 1 and 2 and is involved in regulation of the intra-S and G2/M cell cycle checkpoint arrest for premitotic DNA repair. The Wee1 inhibitor, adavosertib, has demonstrated activity alone and in combination with olaparib in PARP inhibitor (PARPi)-resistant preclinical models.
Shannon Neville Westin, Robert L. Coleman, Bryan M. Fellman, Ying Yuan, Anil K. Sood, Pamela T. Soliman, Alexi A. Wright, Neil S. Horowitz, Susana M. Campos, Panagiotis A. Konstantinopoulos, Charles F. Levenback, David Marc Gershenson, Karen H. Lu, Virginia Bayer, Sobiya Tukdi, Alexis Rabbit, Lone Ottesen, Robert Godin, Gordon B. Mills, Joyce F. Liu   +19 more
openaire   +1 more source

Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma

Journal of Clinical Oncology, 2021
PURPOSEUterine serous carcinoma (USC) is a distinct histologic subtype of endometrial cancer, with molecular characteristics suggesting frequent cell-cycle dysregulation paired with a high level of oncogene-driven replication stress. Adavosertib is a potent and selective oral inhibitor of the WEE1 kinase, a key regulator of the G2/M and S phase cell ...
Joyce F. Liu, Niya Xiong, Susana M. Campos, Alexi A. Wright, Carolyn Krasner, Susan Schumer, Neil Horowitz, Jennifer Veneris, Nabihah Tayob, Stephanie Morrissey, Gabriela West, Roxanne Quinn, Ursula A. Matulonis, Panagiotis A. Konstantinopoulos   +13 more
openaire   +2 more sources

Population Pharmacokinetic Modeling of Adavosertib (AZD1775) in Patients with Solid Tumors

Journal of Clinical Pharmacology
AbstractAdavosertib (AZD1775) is a potent small‐molecule inhibitor of Wee1 kinase. This analysis utilized pharmacokinetic data from 8 Phase I/II studies of adavosertib to characterize the population pharmacokinetics of adavosertib in patients (n = 538) with solid tumors and evaluate the impact of covariates on exposure.
Daniel Kaschek, Ganesh Mugundu, Martin Johnson   +2 more
exaly   +3 more sources

Adavosertib Is Safe and Efficacious in CCNE1-Amplified Solid Tumors

Cancer Discovery, 2023
Abstract Adavosertib shows safety and promising antitumor efficacy in advanced CCNE1-amplified solid tumors.
openaire   +2 more sources

A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2 - Altered Advanced Solid Tumor Malignancies (NCI 10170) [PDF]

Cancer Research Communications
We sought to evaluate the efficacy of WEE1 inhibitor adavosertib in patients with solid tumor malignancies (cohort A) and clear cell renal cell carcinoma (ccRCC; cohort B). NCT03284385 was a parallel cohort, Simon two-stage, phase II study of adavosertib
Jordi Rodón, Rahul Aggarwal, Patricia Lorusso   +2 more
exaly   +4 more sources

Synergistic effect of adavosertib and fimepinostat on acute myeloid leukemia cells by enhancing the induction of DNA damage

Investigational New Drugs, 2023
In recent years, a number of novel pharmaceutical agents have received approval for the management of acute myeloid leukemia (AML). However, there is still ample opportunity for enhancing efficacy. The Wee1 inhibitor adavosertib (ADA) shows promise for the treatment of AML.
Yue, Wang, Xingyu, Lin, Yue, Wang, Guan, Wang   +3 more
openaire   +2 more sources

A phase II trial of the Wee1 inhibitor adavosertib (AZD1775) in recurrent uterine serous carcinoma.

Journal of Clinical Oncology, 2020
6009 Background: Uterine serous carcinoma (USC) is an aggressive subtype of endometrial carcinoma characterized by TP53 mutations ( > 90%), often concomitantly with oncogenic mutations or amplifications that can increase replication stress. As such, USC may therefore be uniquely sensitive to further interference of cell cycle regulation by Wee1 ...
Joyce F. Liu, Niya Xiong, Susana M. Campos, Alexi A. Wright, Carolyn N. Krasner, Susan T. Schumer, Neil S. Horowitz, Jennifer Taylor Veneris, Nabihah Tayob, Stephanie Morrissey, Gabriela West, Roxanne Quinn, Ursula A. Matulonis, Panagiotis A. Konstantinopoulos   +13 more
openaire   +2 more sources

Intratumoral drug distribution of adavosertib in patients with glioblastoma: Interim results of phase I study.

Journal of Clinical Oncology, 2020
2568 Background: Wee1 is a key regulator of the G2/M checkpoint and is frequently overexpressed in glioblastoma (GB). Adavosertib is a first-in-class oral, small molecule inhibitor of Wee1 that acts primarily as a DNA damage sensitizer. A phase I clinical trial was conducted to evaluate its safety and establish the recommended phase II dosing ...
Carlos G Romo, Brian Michael Alexander, Nathalie Agar, Manmeet Singh Ahluwalia, Arati Suvas Desai, Jorg Dietrich, Thomas Joseph Kaley, David M. Peereboom, Naoko Takebe, Serena Desideri, Joy D. Fisher, Megan Sims, Xiaobu Ye, Keith L. Ligon, Louis B. Nabors, Patrick Y. Wen, Stuart A. Grossman, Jeffrey G. Supko, Eudocia Quant Lee   +18 more
openaire   +1 more source

ADAGIO: a phase IIb international study of the Wee1 inhibitor adavosertib in women with recurrent or persistent uterine serous carcinoma

International Journal of Gynecological Cancer, 2022
Uterine serous carcinoma is a distinct histologic subtype of endometrial cancer with an aggressive phenotype, poor prognosis, and limited therapeutic options. A previous proof-of-concept phase II trial of the Wee1 inhibitor adavosertib in uterine serous carcinoma demonstrated evidence of durable clinical activity.To evaluate the efficacy of adavosertib
Ana Oaknin, Amit Oza, Nicoletta Colombo   +2 more
exaly   +3 more sources